1 | significance | 10,384 |
2 | significances | 45 |
3 | signification | 9 |
4 | yearbook | 8 |
5 | cephadroxyl | 5 |
6 | significancy | 5 |
7 | non-significance | 3 |
8 | significativity | 3 |
9 | 3,4-dihydro-1,2-oxazepin-5 | 2 |
10 | ketopentoses | 2 |
11 | manual-iv | 2 |
12 | nodular-like | 2 |
13 | outliner | 2 |
14 | ≥90°f | 2 |
15 | 'uti | 1 |
16 | 1.07×10 | 1 |
17 | 1.0molh2/molgalactose | 1 |
18 | 1.26.10 | 1 |
19 | 131/752 | 1 |
20 | 174,262 | 1 |
21 | 179-199 | 1 |
22 | 179.97+/-80.58 | 1 |
23 | 2,863,203 | 1 |
24 | 20/mn3 | 1 |
25 | 26cm | 1 |
26 | 28.23g/l | 1 |
27 | 29.54°c | 1 |
28 | 3'-deoxy-3'-azidocytidine | 1 |
29 | 3-4-methylenedioxymethamphetamine | 1 |
30 | 3.6/100,000 | 1 |
31 | 33°c-35°c | 1 |
32 | 35-38mm | 1 |
33 | 357-fold | 1 |
34 | 38.9±0.1°c | 1 |
35 | 4.6°c | 1 |
36 | 4log10cycles | 1 |
37 | 5,5'-dimethyl-3,3'-bi | 1 |
38 | 54gl | 1 |
39 | 6.89e-12 | 1 |
40 | 7.7°c | 1 |
41 | 8.3×mic | 1 |
42 | 86.2g/l | 1 |
43 | 8microgg | 1 |
44 | 98±6u/ml | 1 |
45 | analyses-χ² | 1 |
46 | analyses.no | 1 |
47 | approach-the | 1 |
48 | approaches-unmatched | 1 |
49 | as=10 | 1 |
50 | as=9 | 1 |
51 | differences.values | 1 |
52 | euro8300 | 1 |
53 | factor.the | 1 |
54 | faith3 | 1 |
55 | familiarity/proficiency | 1 |
56 | features-clinical | 1 |
57 | hago2 | 1 |
58 | his190 | 1 |
59 | htgr5 | 1 |
60 | hydroprocessing | 1 |
61 | manual-fourth | 1 |
62 | mental-iv | 1 |
63 | method-network | 1 |
64 | methods-comparison | 1 |
65 | methods3 | 1 |
66 | mg/well | 1 |
67 | micro-ingredients | 1 |
68 | mip-3beta | 1 |
69 | mode-of-actions | 1 |
70 | octamethylfulvene | 1 |
71 | p-nitrophenyl-β-d-mannopyranoside | 1 |
72 | pain.therefore | 1 |
73 | preindustrial | 1 |
74 | pseudo-polymorphism | 1 |
75 | pseudoagouti | 1 |
76 | qubin | 1 |
77 | quirks | 1 |
78 | r-hmea | 1 |
79 | responsibilities-assumed | 1 |
80 | rhodamine-b | 1 |
81 | risk-strata | 1 |
82 | rss-2 | 1 |
83 | s-p-e-c-i-a-l | 1 |
84 | significance.- | 1 |
85 | significance.antibiotic-treated | 1 |
86 | significance.comparing | 1 |
87 | significance.relatively | 1 |
88 | significance.there | 1 |
89 | significance.this | 1 |
90 | summarizations | 1 |
91 | systems'performance | 1 |
92 | trial-reported | 1 |
93 | tumors/adenocarcinomas | 1 |
94 | £40,000 | 1 |
95 | β-adrenoceptor-blocking | 1 |
96 | γ-cyclodextin | 1 |
1 | 'uti | 1 |
2 | 1.07×10 | 1 |
3 | 1.0molh2/molgalactose | 1 |
4 | 1.26.10 | 1 |
5 | 131/752 | 1 |
6 | 174,262 | 1 |
7 | 179-199 | 1 |
8 | 179.97+/-80.58 | 1 |
9 | 2,863,203 | 1 |
10 | 20/mn3 | 1 |
11 | 26cm | 1 |
12 | 28.23g/l | 1 |
13 | 29.54°c | 1 |
14 | 3'-deoxy-3'-azidocytidine | 1 |
15 | 3,4-dihydro-1,2-oxazepin-5 | 2 |
16 | 3-4-methylenedioxymethamphetamine | 1 |
17 | 3.6/100,000 | 1 |
18 | 33°c-35°c | 1 |
19 | 35-38mm | 1 |
20 | 357-fold | 1 |
21 | 38.9±0.1°c | 1 |
22 | 4.6°c | 1 |
23 | 4log10cycles | 1 |
24 | 5,5'-dimethyl-3,3'-bi | 1 |
25 | 54gl | 1 |
26 | 6.89e-12 | 1 |
27 | 7.7°c | 1 |
28 | 8.3×mic | 1 |
29 | 86.2g/l | 1 |
30 | 8microgg | 1 |
31 | 98±6u/ml | 1 |
32 | analyses-χ² | 1 |
33 | analyses.no | 1 |
34 | approach-the | 1 |
35 | approaches-unmatched | 1 |
36 | as=10 | 1 |
37 | as=9 | 1 |
38 | cephadroxyl | 5 |
39 | differences.values | 1 |
40 | euro8300 | 1 |
41 | factor.the | 1 |
42 | faith3 | 1 |
43 | familiarity/proficiency | 1 |
44 | features-clinical | 1 |
45 | hago2 | 1 |
46 | his190 | 1 |
47 | htgr5 | 1 |
48 | hydroprocessing | 1 |
49 | ketopentoses | 2 |
50 | manual-fourth | 1 |
51 | manual-iv | 2 |
52 | mental-iv | 1 |
53 | method-network | 1 |
54 | methods-comparison | 1 |
55 | methods3 | 1 |
56 | mg/well | 1 |
57 | micro-ingredients | 1 |
58 | mip-3beta | 1 |
59 | mode-of-actions | 1 |
60 | nodular-like | 2 |
61 | non-significance | 3 |
62 | octamethylfulvene | 1 |
63 | outliner | 2 |
64 | p-nitrophenyl-β-d-mannopyranoside | 1 |
65 | pain.therefore | 1 |
66 | preindustrial | 1 |
67 | pseudo-polymorphism | 1 |
68 | pseudoagouti | 1 |
69 | qubin | 1 |
70 | quirks | 1 |
71 | r-hmea | 1 |
72 | responsibilities-assumed | 1 |
73 | rhodamine-b | 1 |
74 | risk-strata | 1 |
75 | rss-2 | 1 |
76 | s-p-e-c-i-a-l | 1 |
77 | significance | 10,384 |
78 | significance.- | 1 |
79 | significance.antibiotic-treated | 1 |
80 | significance.comparing | 1 |
81 | significance.relatively | 1 |
82 | significance.there | 1 |
83 | significance.this | 1 |
84 | significances | 45 |
85 | significancy | 5 |
86 | signification | 9 |
87 | significativity | 3 |
88 | summarizations | 1 |
89 | systems'performance | 1 |
90 | trial-reported | 1 |
91 | tumors/adenocarcinomas | 1 |
92 | yearbook | 8 |
93 | £40,000 | 1 |
94 | β-adrenoceptor-blocking | 1 |
95 | γ-cyclodextin | 1 |
96 | ≥90°f | 2 |
1 | significance.- | 1 |
2 | 3.6/100,000 | 1 |
3 | £40,000 | 1 |
4 | euro8300 | 1 |
5 | 1.26.10 | 1 |
6 | as=10 | 1 |
7 | 1.07×10 | 1 |
8 | his190 | 1 |
9 | rss-2 | 1 |
10 | 6.89e-12 | 1 |
11 | 131/752 | 1 |
12 | 174,262 | 1 |
13 | hago2 | 1 |
14 | 2,863,203 | 1 |
15 | faith3 | 1 |
16 | 20/mn3 | 1 |
17 | methods3 | 1 |
18 | 3,4-dihydro-1,2-oxazepin-5 | 2 |
19 | htgr5 | 1 |
20 | 179.97+/-80.58 | 1 |
21 | 179-199 | 1 |
22 | as=9 | 1 |
23 | r-hmea | 1 |
24 | risk-strata | 1 |
25 | mip-3beta | 1 |
26 | rhodamine-b | 1 |
27 | 8.3×mic | 1 |
28 | 38.9±0.1°c | 1 |
29 | 29.54°c | 1 |
30 | 33°c-35°c | 1 |
31 | 4.6°c | 1 |
32 | 7.7°c | 1 |
33 | approaches-unmatched | 1 |
34 | responsibilities-assumed | 1 |
35 | significance.antibiotic-treated | 1 |
36 | trial-reported | 1 |
37 | 357-fold | 1 |
38 | significance | 10,384 |
39 | non-significance | 3 |
40 | systems'performance | 1 |
41 | p-nitrophenyl-β-d-mannopyranoside | 1 |
42 | approach-the | 1 |
43 | factor.the | 1 |
44 | nodular-like | 2 |
45 | octamethylfulvene | 1 |
46 | 3'-deoxy-3'-azidocytidine | 1 |
47 | 3-4-methylenedioxymethamphetamine | 1 |
48 | significance.there | 1 |
49 | pain.therefore | 1 |
50 | 1.0molh2/molgalactose | 1 |
51 | ≥90°f | 2 |
52 | 8microgg | 1 |
53 | β-adrenoceptor-blocking | 1 |
54 | significance.comparing | 1 |
55 | hydroprocessing | 1 |
56 | manual-fourth | 1 |
57 | 5,5'-dimethyl-3,3'-bi | 1 |
58 | 'uti | 1 |
59 | pseudoagouti | 1 |
60 | yearbook | 8 |
61 | method-network | 1 |
62 | s-p-e-c-i-a-l | 1 |
63 | 86.2g/l | 1 |
64 | 28.23g/l | 1 |
65 | features-clinical | 1 |
66 | preindustrial | 1 |
67 | 54gl | 1 |
68 | mg/well | 1 |
69 | 98±6u/ml | 1 |
70 | cephadroxyl | 5 |
71 | 26cm | 1 |
72 | 35-38mm | 1 |
73 | pseudo-polymorphism | 1 |
74 | qubin | 1 |
75 | γ-cyclodextin | 1 |
76 | signification | 9 |
77 | methods-comparison | 1 |
78 | analyses.no | 1 |
79 | outliner | 2 |
80 | tumors/adenocarcinomas | 1 |
81 | significances | 45 |
82 | 4log10cycles | 1 |
83 | ketopentoses | 2 |
84 | differences.values | 1 |
85 | significance.this | 1 |
86 | quirks | 1 |
87 | summarizations | 1 |
88 | mode-of-actions | 1 |
89 | micro-ingredients | 1 |
90 | mental-iv | 1 |
91 | manual-iv | 2 |
92 | significancy | 5 |
93 | familiarity/proficiency | 1 |
94 | significance.relatively | 1 |
95 | significativity | 3 |
96 | analyses-χ² | 1 |